<DOC>
	<DOCNO>NCT02290379</DOCNO>
	<brief_summary>Single-center , randomize , double-blind , placebo-controlled , single ascend dose , safety tolerability study TNX-201 capsule healthy volunteer .</brief_summary>
	<brief_title>Phase 1 Single Ascending Dose Safety Study TNX-201 Capsules Healthy Volunteers</brief_title>
	<detailed_description>Single-center , randomize , double-blind , placebo-controlled , single ascend dose , safety tolerability study TNX-201 capsule healthy volunteer . Three successive cohort plan dos TNX-201 capsule , 35 mg , 70 mg , 140 mg , respectively . Each cohort consist 15 subject , subject randomly assign TNX-201 , racemic isometheptene , placebo capsule .</detailed_description>
	<criteria>1 . Male female , ≥ 18 ≤ 55 year age day randomization . NOTE : At least 6 female subject need randomize cohort . 2 . Body mass index ( BMI ) ≥18.5 ≤33.0 3 . Nontobacco user ( use tobacco nicotine containing product within 3 month prior study drug administration ) 1 . Any clinically significant abnormality clinically significant abnormal laboratory test result find Screening Day 1 , positive test HBsAg , HCAb , HIV find Screening 2 . Positive urine drug screen ( include alcohol , tetrahydrocannabinol ( THC ) , cocaine , amphetamine , opiate ) urine cotinine test Screening Day 1 3 . Known suspected hypersensitivity isometheptene mucate excipients use formulation . 4 . Positive serum pregnancy test Screening Day 1 5 . Any reason , opinion Principal Investigator ( PI ) sponsor 's Medical Monitor , prevent subject participate study 6 . Clinically significant ECG abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>